Combating respiratory diseases with mucosal vaccines.

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Respiratory infections pose a significant global health challenge.
• Parenteral vaccines primarily induce systemic immunity, which is less effective at the site of infection.
• Mucosal vaccines stimulate local immune responses, offering advantages for preventing respiratory diseases.

Purpose of the Study:

• To review recent advances in mucosal vaccine platforms and delivery strategies for respiratory viruses.
• To highlight key immune components and mechanisms of mucosal immunity.
• To discuss the translational and clinical implications for next-generation vaccine design and pandemic preparedness.

Main Methods:

• Review of scientific literature focusing on mucosal vaccine platforms and delivery strategies.
• Analysis of findings from both animal models and human studies.
• Examination of immune components and mechanisms involved in mucosal immunity.

Main Results:

• Mucosal vaccines induce robust local immune responses, including secretory IgA, tissue-resident memory T and B cells, and mucosal IgG.
• These responses effectively block viral entry, limit replication, and reduce transmission at the mucosal surface.
• Recent advances include novel vaccine platforms, adjuvants, and heterologous prime-boost approaches.

Conclusions:

• Mucosal vaccines provide rapid, durable protection directly at the site of respiratory infection.
• Advances in mucosal vaccine technology are crucial for developing next-generation vaccines against respiratory viruses.
• Mucosal vaccines are essential for strengthening future pandemic preparedness.